4XUF

Crystal structure of the FLT3 kinase domain bound to the inhibitor quizartinib (AC220)


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.2 Å
  • R-Value Free: 0.320 
  • R-Value Work: 0.297 

wwPDB Validation 3D Report Full Report


This is version 1.4 of the entry. See complete history

Literature

Crystal Structure of the FLT3 Kinase Domain Bound to the Inhibitor Quizartinib (AC220).

Zorn, J.A.Wang, Q.Fujimura, E.Barros, T.Kuriyan, J.

(2015) Plos One 10: e0121177-e0121177

  • DOI: 10.1371/journal.pone.0121177

  • PubMed Abstract: 
  • More than 30% of acute myeloid leukemia (AML) patients possess activating mutations in the receptor tyrosine kinase FMS-like tyrosine kinase 3 or FLT3. A small-molecule inhibitor of FLT3 (known as quizartinib or AC220) that is currently in clinical t ...

    More than 30% of acute myeloid leukemia (AML) patients possess activating mutations in the receptor tyrosine kinase FMS-like tyrosine kinase 3 or FLT3. A small-molecule inhibitor of FLT3 (known as quizartinib or AC220) that is currently in clinical trials appears promising for the treatment of AML. Here, we report the co-crystal structure of the kinase domain of FLT3 in complex with quizartinib. FLT3 with quizartinib bound adopts an "Abl-like" inactive conformation with the activation loop stabilized in the "DFG-out" orientation and folded back onto the kinase domain. This conformation is similar to that observed for the uncomplexed intracellular domain of FLT3 as well as for related receptor tyrosine kinases, except for a localized induced fit in the activation loop. The co-crystal structure reveals the interactions between quizartinib and the active site of FLT3 that are key for achieving its high potency against both wild-type FLT3 as well as a FLT3 variant observed in many AML patients. This co-complex further provides a structural rationale for quizartinib-resistance mutations.


    Organizational Affiliation

    Department of Molecular and Cell Biology, University of California, Berkeley, California, United States of America.,Department of Molecular and Cell Biology, University of California, Berkeley, California, United States of America; California Institute for Quantitative Biosciences, University of California, Berkeley, California, United States of America; Howard Hughes Medical Institute, University of California, Berkeley, California, United States of America.,Department of Molecular and Cell Biology, University of California, Berkeley, California, United States of America; California Institute for Quantitative Biosciences, University of California, Berkeley, California, United States of America; Howard Hughes Medical Institute, University of California, Berkeley, California, United States of America; Department of Chemistry, University of California, Berkeley, California, United States of America; Physical Biosciences Division, Lawrence Berkeley National Laboratory, Berkeley, California, United States of America.,Department of Molecular and Cell Biology, University of California, Berkeley, California, United States of America; California Institute for Quantitative Biosciences, University of California, Berkeley, California, United States of America.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Receptor-type tyrosine-protein kinase FLT3
A, B
297Homo sapiensMutation(s): 0 
Gene Names: FLT3 (CD135, FLK2, STK1)
EC: 2.7.10.1
Find proteins for P36888 (Homo sapiens)
Go to Gene View: FLT3
Go to UniProtKB:  P36888
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
P30
Query on P30

Download SDF File 
Download CCD File 
A, B
1-(5-tert-butyl-1,2-oxazol-3-yl)-3-(4-{7-[2-(morpholin-4-yl)ethoxy]imidazo[2,1-b][1,3]benzothiazol-2-yl}phenyl)urea
Quizartinib, PLX3397
C29 H32 N6 O4 S
CVWXJKQAOSCOAB-UHFFFAOYSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
P30IC50: 2 - 137 nM (85) BINDINGDB
P30Kd: 1.3 - 8.8 nM (85) BINDINGDB
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.2 Å
  • R-Value Free: 0.320 
  • R-Value Work: 0.297 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 48.726α = 90.00
b = 75.492β = 90.00
c = 153.968γ = 90.00
Software Package:
Software NamePurpose
HKL-2000data scaling
PHENIXrefinement
HKL-2000data reduction
PHENIXphasing
PDB_EXTRACTdata extraction

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Institutes of Health/National Cancer Institute (NIH/NCI)United StatesF32 CA177087-02
Cancer Research InstituteUnited States--
Howard Hughes Medical Institute (HHMI)United States--

Revision History 

  • Version 1.0: 2015-04-15
    Type: Initial release
  • Version 1.1: 2015-04-29
    Type: Database references
  • Version 1.2: 2015-08-26
    Type: Experimental preparation
  • Version 1.3: 2017-09-06
    Type: Author supporting evidence, Derived calculations
  • Version 1.4: 2019-11-20
    Type: Author supporting evidence